Editas Medicine (EDIT) Misses Q3 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts EDIT Hot Sheet
Join SI Premium – FREE
Editas Medicine (NASDAQ: EDIT) reported Q3 EPS of ($0.64), $0.04 worse than the analyst estimate of ($0.60).
For earnings history and earnings-related data on Editas Medicine (EDIT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Real Industry (RELY) Tops Q3 EPS by 15c; offers guidance
- Compass Diversified (CODI) Misses Q3 EPS by 2c
- Deluxe Corp. (DLX) Tops Q3 EPS by 11c; offers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
